KRAS mutations were noted to be the most common mutation in HER2-amplified CRC (21.8%, 19/87), with rates notably higher in HER2-amplified colon cancer (27.9%, 17/61) and lower in HER2-amplified rectal cancer (7.7%, 2/26). This evidence concerns the gene ERBB2 and malignant colon neoplasm.